$1.19
-0.01 (-0.83%)
Open$1.22
Previous Close$1.20
Day High$1.23
Day Low$1.18
52W High$19.03
52W Low$0.97
Volume—
Avg Volume148.0K
Market Cap5.73M
P/E Ratio—
EPS$-9.17
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+568.1% upside
Current
$1.19
$1.19
Target
$7.95
$7.95
$5.82
$7.95 avg
$9.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 913.8K | 821.5K | 988.8K |
| Net Income | -134,164 | -149,522 | -162,197 |
| Profit Margin | -14.7% | -18.2% | -16.4% |
| EBITDA | -201,888 | -178,889 | -216,043 |
| Free Cash Flow | -124,461 | -98,758 | -111,181 |
| Rev Growth | +16.4% | +11.0% | +21.1% |
| Debt/Equity | 1.08 | 0.86 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |